Practical aspects of risk assessment in gastrointestinal stromal tumors

被引：24

作者：

Jones R.L. ^{[1
]}

机构：

[1] Division of Medical Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109-1023, 825 Eastlake Avenue East

来源：

Journal of Gastrointestinal Cancer | 2014年 / 45卷 / 3期

关键词：

Adjuvant therapy; Gastrointestinal stromal tumors; GIST; Imatinib; Risk; Risk assessment;

D O I：

10.1007/s12029-014-9615-x

中图分类号：

学科分类号：

摘要：

Introduction: Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract, which are characterized in the majority of cases by activating mutations in KIT and platelet-derived growth factor receptor alpha (PDGFRA). The introduction of tyrosine kinase inhibitors has revolutionized the management of patients with metastatic GIST. However, complete surgical resection remains the mainstay of management for those with localized disease. Recently, three large trials have confirmed the benefit of adjuvant imatinib therapy in patients who were at high risk of recurrence following complete resection. In this setting, it is critical that oncologists understand the various GIST risk assessment criteria and be able to apply these methods to accurately assess the risk of recurrence and the need for adjuvant imatinib therapy. Purpose: The aim of this review is to outline the risk stratification systems currently available to oncologists who are treating patients with GIST, so they can be optimally applied for clinical decision-making. © The Author(s) 2014.

引用

页码：262 / 267

页数：5

共 44 条

[1]

Corless C.L., Heinrich M.C., Molecular pathobiology of gastrointestinal stromal sarcomas, Annual Review of Pathology: Mechanisms of Disease, 3, pp. 557-586, (2008)

[2]

Miettinen M., Lasota J., Gastrointestinal stromal tumors: Pathology and prognosis at different sites, Seminars in Diagnostic Pathology, 23, 2, pp. 70-83, (2006)

[3]

Gold J.S., Gonen M., Gutierrez A., Broto J.M., Garcia-del-Muro X., Smyrk T.C., Et al., Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis, Lancet Oncol, 10, 11, pp. 1045-1052, (2009)

[4]

DeMatteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., Et al., Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, doubleblind, placebo-controlled trial, Lancet, 373, 9669, pp. 1097-1104, (2009)

[5]

Joensuu H., Eriksson M., Sundby Hall K., Hartmann J.T., Pink D., Schutte J., Et al., One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial, JAMA, 307, 12, pp. 1265-1272, (2012)

[6]

Dematteo R.P., Ballman K.V., Antonescu C.R., Corless C., Kolesnikova V., Von Mehren M., Et al., Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) Intergroup phase 2 trial, Ann Surg, 258, 3, (2013)

[7]

NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, (2013)

[8]

Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, SUPPL. 7, (2012)

[9]

Casali P.G., Le Cesne A., Velasco A.P., Kotasek D., Rutkowski P., Hohenberger P., Fumagalli E., Judson I.R., Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial, J Clin Oncol, 31, 15 SUPPL., (2013)

[10]

Fletcher C.D.M., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.Jack, Miettinen M., O'Leary T.J., Remotti H., Rubin B.P., Shmookler B., Sobin L.H., Weiss S.W., Diagnosis of gastrointestinal stromal tumors: A consensus approach, Human Pathology, 33, 5, pp. 459-465, (2002)

← 1 2 3 4 5 →